Hypoxia inducible factor-1 alpha (HIF-1α) is thought to play a role in melanoma carcinogenesis. Posttranslational regulation of HIF-1αis dependent on Prolyl hydroxylase (PHD 1-3) and Factor Inhibiting HIF (FIH) hydroxylase enzymes, which require ascorbic acid as a co-factor for optimal function.
MRV Research
Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers
Incyte Corporation announces the first presentation of findings from the ongoing proof-of-concept Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, in combination with pembrolizumab, an anti-PD-1 therapy. Results evaluating 19 patients for efficacy and 28 patients for safety, indicate a 79 percent (n=15/19) disease control rate (DCR) in evaluable patients with advanced cancers. Responses were observed in all tumor types assessed. In the melanoma group (n=7), four of seven patients treated with the combination of epacadostat and pembrolizumab had an objective response, including 2 complete responses (CRs), with disease control demonstrated in six of the seven patients treated with the combination.
Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy
Biodesix, Inc. today announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy.1 Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being presented at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD.
Vitiligo association with metastatic melanoma survival tops October dermatology reads
Study results finding a possible association between the onset of vitiligo and clinical benefit of Keytruda in patients with metastatic melanoma was the most-read article in October on Healio.com/Dermatology.